论文部分内容阅读
目的探讨Ⅱb~Ⅲ期宫颈癌同期放化疗后口服尿嘧啶替加氟维持化疗的疗效及不良反应。方法 85例Ⅱb~Ⅲ期宫颈癌患者,随机分为两组,其中维持化疗组40例,该组患者同期放化疗完成后给予口服尿嘧啶替加氟维持化疗至少1年,对照组45例仅随访观察。比较两组患者近期疗效及不良反应。结果维持化疗组无进展生存时间较对照组延长,中位无进展生存时间分别为32个月与27个月,差异有统计学意义(P=0.022<0.05)。两组骨髓抑制及胃肠道反应发生率比较,差异无统计学意义(P>0.05)。结论口服尿嘧啶替加氟维持化疗可改善Ⅱb~Ⅲ期宫颈癌生存质量,且未明显增加毒性反应,有望在临床上推广使用。
Objective To investigate the curative effect and side effects of oral uracil and tegafur chemotherapy in patients with stage Ⅱb-Ⅲ cervical cancer after concurrent chemoradiotherapy. Methods A total of 85 patients with stage Ⅱb-Ⅲ cervical cancer were randomly divided into two groups, of which 40 patients in the chemotherapy group were maintained. Oral uracil and tegafur maintenance chemotherapy was given for at least 1 year after the completion of concurrent chemoradiotherapy in this group. In the control group, 45 patients Follow-up observation. Short-term efficacy and adverse reactions were compared between the two groups. Results The duration of progression-free survival in the chemotherapy group was longer than that in the control group. The median progression-free survival time was 32 months and 27 months, respectively, with significant difference (P = 0.022 <0.05). There was no significant difference between the two groups in the incidence of bone marrow suppression and gastrointestinal reaction (P> 0.05). Conclusion Oral uracil and tegafur maintenance chemotherapy can improve the quality of life of stage Ⅱb ~ Ⅲ cervical cancer, and no significant increase in toxicity, is expected to be widely used in clinical practice.